Antibodies

22 Jul 2022 I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
21 Jul 2022 Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
21 Jul 2022 Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
21 Jul 2022 F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
20 Jul 2022 DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
20 Jul 2022 Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
19 Jul 2022 ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
18 Jul 2022 Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
18 Jul 2022 EMA Validates Marketing Authorization Application for Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer
16 Jul 2022 HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China
14 Jul 2022 Hemab Therapeutics Presents New Data on HMB-001 for the Treatment of Glanzmann Thrombasthenia and Other Bleeding Disorders at 2022 ISTH Congress
14 Jul 2022 Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
14 Jul 2022 Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Advanced Solid Tumors
13 Jul 2022 Y-mAbs’ Announces Clearance of IND for GD2-SADA
12 Jul 2022 FDA Accepts Byondis' Biologics License Application for [Vic-] Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer
12 Jul 2022 Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates potential as once monthly treatment for people with haemophilia A
12 Jul 2022 Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
11 Jul 2022 Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
11 Jul 2022 Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis
09 Jul 2022 MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
08 Jul 2022 Sobi to license loncastuximab tesirine from ADC Therapeutics
07 Jul 2022 CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
07 Jul 2022 Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
07 Jul 2022 SunHo Announces First Patient Dosed in Phase 1/2 Clinical Trial of Two First-in-class Immunocytokines: IAP0971 and IAE0972
06 Jul 2022 Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top